Browsing Pathways
Showing 131 -
140 of 605359 pathways
PathBank ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0143474View Pathway |
Abacavir Drug Metabolism Action PathwayHomo sapiens
|
Metabolite
Drug Action
|
|
|
SMP0130072View Pathway |
Abagovomab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0127856View Pathway |
Abaloparatide Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0144801View Pathway |
Abametapir Drug Metabolism Action PathwayHomo sapiens
|
Metabolite
Drug Action
|
|
|
SMP0142593View Pathway |
Abarelix Drug Metabolism Action PathwayHomo sapiens
|
Metabolite
Drug Action
|
|
|
SMP0127806View Pathway |
Abatacept Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0126564View Pathway |
Abciximab Action PathwayBos taurus
Abciximab or Abcixifiban is a platelet aggregation inhibitor drug sold under the name ReoPro. It is administered intravenously, and can act to decrease platelet aggregation for up to two days after administration. Abciximab is an antigen binding fragment that targets glycoprotein IIb/IIIa receptors on the outer membrane of platelets.
In the vein, Abciximab causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion.
|
Metabolite
Drug Action
|
|
|
SMP0126565View Pathway |
Abciximab Action PathwayMus musculus
Abciximab or Abcixifiban is a platelet aggregation inhibitor drug sold under the name ReoPro. It is administered intravenously, and can act to decrease platelet aggregation for up to two days after administration. Abciximab is an antigen binding fragment that targets glycoprotein IIb/IIIa receptors on the outer membrane of platelets.
In the vein, Abciximab causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion.
|
Metabolite
Drug Action
|
|
|
SMP0121127View Pathway |
Abciximab Action PathwayHomo sapiens
Abciximab or Abcixifiban is a platelet aggregation inhibitor drug sold under the name ReoPro. It is administered intravenously, and can act to decrease platelet aggregation for up to two days after administration. Abciximab is an antigen binding fragment that targets glycoprotein IIb/IIIa receptors on the outer membrane of platelets.
In the vein, Abciximab causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion.
|
Metabolite
Drug Action
|
|
|
SMP0000265View Pathway |
Abciximab Action Pathway (old)Homo sapiens
Abciximab (also known as c7E3 Fab) is integrin (integrin alpha-IIb and integrin beta-3) receptor antagonist. Binding of abciximab to integrin receptor will block any large molecule to attach on the receptor, which will lead to block any associated signal transduction pathways.
|
Metabolite
Drug Action
|
|
Showing 131 -
140 of 167268 pathways